STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
“Some immunologically relevant genes that can become mutated in cancers include JAK1, JAK2, B2M, STK11, and others [51, 52].”
BackgroundThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationThe 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Self-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
“Recently, STK11/LKB1 co-mutation in KRAS-mutant NSCLC was reported as a new predictive marker for tumor resistance to ICI therapy [21].”
BackgroundSelf-citationHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAdvances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
“I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
BackgroundThe Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Self-citationThe lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., McGraw, T., & Mittal, V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,150
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Self-citationTargeting Autophagy in Cancer: Recent Advances and Future Directions
Amaravadi, R. K., Kimmelman, A. C., & Debnath, J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0292 · Cited by 928
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
“However, if the KRAS-mutant tumor also harboured an STK11 mutation, this was associated with reduced PD-L1 levels; or if it harboured a KEAP mutation, there was an associated reduction in T-cell infiltration and downregulation of inflammatory cytokines 70,79,82,83 .”
Self-citationImmunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1538 · Cited by 667
“A number of TC-intrinsic signaling pathways implicated in the setting of primary resistance may also be relevant to acquired resistance, including upregulation of PD-L1 (82, 83), loss of PTEN (84, 85), loss-of-function mutations of STK11/ LKB1 (86, 87), activation of c-Myc (88), activation of the WNT/b-catenin pathway…”
BackgroundShu, C. A., Gainor, J. F., Awad, M. M., Chiuzan, C., Grigg, C. M., Pabani, A., Garofano, R. F., Stoopler, M. B., Cheng, S. K., White, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30140-6 · Cited by 623
Self-citationImmune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
“KRAS-mutant lung cancers are resistant to PD1/PD-L1 blockade due to the suppression of STING associated with LKB1 loss.(131,132) BRCA1-deficient ovarian cancers mediate immune resistance through transcriptional reprogramming and cellintrinsic inflammation via the STING pathway.”
BackgroundHendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
“65,66) or a baseline mutation in the TSG SMARCA4 can reduce the efficacy of ICBs 67 .”
Self-citationThe role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Caushi, J. X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E. H.-C., Mog, B. J., Hou, W., Justesen, S., Blosser, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03752-4 · Cited by 543
Self-citationThe current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Self-citationSuppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526
“In particular, although KRAS-TP53 (KP) lung tumors engage the PD-1/ PD-L1 immune checkpoint, KRAS-LKB1 (KL) tumors lack PD-L1 expression and fail to respond to immune checkpoint blockade (ICB; ref.”
BackgroundInfluentialSelf-citationComparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 511
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 471
“and ARID1A can predict non-response to ICIs in high TMB tumors [46]; NSCLC with KRAS and STK11 comutated was associated with reduced response and shorter survival in three independent cohorts of patients treated with anti-PD-1 therapy [47], and STK11 deficiency was an independent indicator of poor anti-PD-1 response i…”
BackgroundHanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 456
Self-citationGenomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 421
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Patil, N. S., Nabet, B. Y., Müller, S., Koeppen, H., Zou, W., Giltnane, J., Au-Yeung, A., Srivats, S., Cheng, J. H., Takahashi, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.002 · Cited by 408
Enhancing anti-tumour efficacy with immunotherapy combinations
Meric-Bernstam, F., Larkin, J., Tabernero, J., & Bonini, C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32598-8 · Cited by 409
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 403
“lack fo benefit from PD-1 blockade (7% overall response) in KRAS-mutant lung adenocarcinomas, a phenomenon that cannot be related to KRAS mutations in that KRAS-mutant lung adenocarcinomas without LKB1 mutations are responsive (about 35% of overall responses) to PD-1 blocking [354].”
BackgroundImmune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
Vanguri, R. S., Luo, J., Aukerman, A. T., Egger, J. V., Fong, C. J., Horvat, N., Pagano, A., Araujo-Filho, J. D. A. B., Geneslaw, L., Rizvi, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00416-8 · Cited by 395
Self-citationRicciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394
Self-citationKlempner, S. J., Fabrizio, D., Bane, S., Reinhart, M., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G., Schrock, A. B., Anhorn, R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0244 · Cited by 391
“Additionally, KRAS mutations have been associated with improved treatment outcomes in NSCLC [30, 82, 84, 85], and certain classes of alterations in JAK1, MDM2/MDM4, ARID1A, and STK11 have predicted a lack of response to ICPIs in a high 20.”
BackgroundSelf-citationLeader, A. M., Grout, J. A., Maier, B. B., Nabet, B. Y., Park, M. D., Tabachnikova, A., Chang, C., Walker, L., Lansky, A., Le Berichel, J., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.009 · Cited by 365
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Mamdani, H., Matosevic, S., Khalid, A. B., Durm, G., & Jalal, S. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.823618 · Cited by 359
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Mechanisms of Cancer Resistance to Immunotherapy
Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 353
“Primary drug resistance, also known as intrinsic resistance, represents a clinical situation in which Abbreviations: ICIs, immune checkpoint inhibitors; PD-1/PD-L1, programmed cell death-1/programmed cell death-ligand 1; NSCLC, non–small cell lung cancer; TME, tumor microenvironment; HPD, hyperprogression; MDM2/4, mur…”
BackgroundInfluentialSinghal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“https://doi.org/10.1038/s41591-024-02903-0 NSCLC 16,17 ; similar results were reported from the phase 1/1b KRYSTAL-1 study, in which adagrasib demonstrated an ORR of 42.9% and a PFS of 6.5 months 18,19 .”
InfluentialImplementing TMB measurement in clinical practice: considerations on assay requirements
Büttner, R., Longshore, J. W., López-Ríos, F., Merkelbach-Bruse, S., Normanno, N., Rouleau, E., & Penault-Llorca, F. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000442 · Cited by 345
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Reck, M., Carbone, D. P., Garassino, M., & Barlesi, F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.001 · Cited by 326
Aguilar, E. J., Ricciuti, B., Gainor, J. F., Kehl, K. L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L. M., Adeni, A., Subegdjo, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz288 · Cited by 338
Self-citationExpanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Bodor, J. N., Boumber, Y., & Borghaei, H. (2020) · Cancer · doi:10.1002/cncr.32468 · Cited by 329
“Tumors with an STK11/LKB1 genomic alteration treated with a checkpoint inhibitor demonstrated inferior clinical outcomes, including in tumors that were PD-L1–positive.31 While underlying factors that explain why certain tumor genotypes do not respond to checkpoint 266 Cancer January 15, 2020 inhibition continue to be…”
BackgroundDatar, I., Sanmamed, M. F., Wang, J., Henick, B. S., Choi, J., Badri, T., Dong, W., Mani, N., Toki, M., Mejías, L. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4142 · Cited by 326
“However, a fraction of NSCLCs with KRAS driver mutations may also harbor other genomic variants which could alter the tumor– immune microenvironment (41).”
BackgroundSelf-citationClinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P., Beras, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.065 · Cited by 324
Self-citationBiomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J., Antonia, S., Mok, T., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 303
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03570 · Cited by 300
Self-citationWnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Negrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bara, I., Shen, V., Xu, H., Hu, S., Sui, D., Elamin, Y. Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002891 · Cited by 294
Self-citationLung cancer in patients who have never smoked — an emerging disease
LoPiccolo, J., Gusev, A., Christiani, D. C., & Jänne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 286
“133,134).”
Bhat, G. R., Sethi, I., Sadida, H. Q., Rah, B., Mir, R., Algehainy, N., Albalawi, I. A., Masoodi, T., Subbaraj, G. K., Jamal, F., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10172-z · Cited by 281
“However, the enthusiasm for these novel therapies is tempered by significant hurdles in their application across multiple cancer types, including lung adenocarcinoma [184, 185], melanoma [186], and pancreatic malignancies [187].”
BackgroundSholl, L. M., Hirsch, F. R., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 283
Self-citationAntitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Liu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 281
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Self-citationImproved prediction of immune checkpoint blockade efficacy across multiple cancer types
Chowell, D., Yoo, S.-K., Valero, C., Pastore, A., Krishna, C., Lee, M., Hoen, D., Shi, H., Kelly, D. W., Patel, N., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01070-8 · Cited by 260
“…immune microenvironment 45–49 ; microbiome composition 50 ; diversity of the T cell receptor repertoire 51 ; specific tumor genomic alterations 52–56 , as mutations of DNA damage response and repair-related genes 57,58 or mutations associated with resistance to ICB; and transcriptomic data might…”
BackgroundGenova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 260
“Several reports have demonstrated that tumors with a high TMB, like NSCLC, possess a high number of neoantigens.”
BackgroundInfluentialSelecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 255
Wohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, À., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108444 · Cited by 246
“We have previously reported STK11 mutations in the context of KRAS-mutant LUAD to be strongly associated with resistance to immunotherapy (Skoulidis et al., 2018).”
Self-citationTargeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 245
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220
Self-citationMetabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Papillon-Cavanagh, S., Doshi, P., Dobrin, R., Szustakowski, J., & Walsh, A. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000706 · Cited by 235
Self-citationReckamp, K. L., Redman, M. W., Dragnev, K. H., Minichiello, K., Villaruz, L. C., Faller, B., Al Baghdadi, T., Hines, S., Everhart, L., Highleyman, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00912 · Cited by 233
Self-citationEl Osta, B., Behera, M., Kim, S., Berry, L. D., Sica, G., Pillai, R. N., Owonikoko, T. K., Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.020 · Cited by 232
“Conversely, never-smokers and patients with EGFR and ALK gene abnormalities are less likely to respond to ICI.”
BackgroundInfluentialSelf-citationWang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
“This also reflected statistically lower time to progression (TTP) in patients having both mutations in KRAS and STK11 genes compared to the tumor with only KRAS mutations (90).”
BackgroundSelf-citationThe cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 231
Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)
Jeanson, A., Tomasini, P., Souquet-Bressand, M., Brandone, N., Boucekine, M., Grangeon, M., Chaleat, S., Khobta, N., Milia, J., Mhanna, L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.011 · Cited by 231
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Mino-Kenudson, M., Schalper, K., Cooper, W., Dacic, S., Hirsch, F. R., Jain, D., Lopez-Rios, F., Tsao, M. S., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 226
“for KRASKEAP1 adenocarcinoma.(53,54) Both mutations confer a worse prognosis and resistance to ICIs in KRAS-mutant tumors.”
BackgroundSelf-citationMarinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D'Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2105 · Cited by 221
Cascone, T., Leung, C. H., Weissferdt, A., Pataer, A., Carter, B. W., Godoy, M. C. B., Feldman, H., William, W. N., Xi, Y., Basu, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02189-0 · Cited by 215
Self-citationMemon, D., Schoenfeld, A. J., Ye, D., Fromm, G., Rizvi, H., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.013 · Cited by 207
Self-citationLa Fleur, L., Falk-Sörqvist, E., Smeds, P., Berglund, A., Sundström, M., Mattsson, J. S., Brandén, E., Koyi, H., Isaksson, J., Brunnström, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.003 · Cited by 207
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 207
“A number of studies have suggested other potential biomarkers, including tumor clonality (20), somatic mutations in specific genes (21), and copy-number alterations (CNA) affecting genes and signaling pathways with important immune-related functions (22, 23).”
BackgroundZhang, M., Yang, W., Wang, P., Deng, Y., Dong, Y.-T., Liu, F.-F., Huang, R., Zhang, P., Duan, Y.-Q., Liu, X.-D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19973-6 · Cited by 207
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C.-Y., Yang, J. C.-H., & Yang, P.-C. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 203
Li, F., Huang, Q., Luster, T. A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0780 · Cited by 203
Self-citationComutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203
Self-citationNew clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Judd, J., Abdel Karim, N., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0201 · Cited by 194
“In 2018, Skoulidis and colleagues showed that STK11/LKB1 co-mutations were associated with a shorter PFS and OS when treated with immune checkpoint inhibitors (6).”
BackgroundMCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Qian, Y., Galan-Cobo, A., Guijarro, I., Dang, M., Molkentine, D., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 193
Self-citationExisting and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 195
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 195
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
“Moreover, alterations in other genes involved in cancer metabolism namely LKB1, and MYC were associated with resistance to ICIs through their potential to hijack the immune system and promote the immunosuppressive milieu of the TME [95, 96].”
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194
Self-citationRavi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
Self-citation
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.